Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
Zymeworks
About
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
- Vancouver,British Columbia,Canada
- 101 - 250
- http://zymeworks.com
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $61.50M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Apr 1, 2004
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nyse:ZYME
- Legal Name
- Zymeworks Inc.
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases.Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization.It was founded in 2004 and headquartered in Vancouver, British Columbia.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 26, 2022 | Post-IPO Equity | $100M | — | — | — | Detail |
| Jan 27, 2020 | Post-IPO Equity | $320.80M | — | — | — | Detail |
| Nov 6, 2019 | Post-IPO Equity | — | 2 | — | — | Detail |
| Jun 28, 2019 | Post-IPO Equity | $201.30M | — | — | — | Detail |
| Jun 8, 2018 | Post-IPO Equity | $97.80M | 5 | — | — | Detail |
Investors
Employee Profiles
Acquisition
Zymeworks has acquired 1 organizations. Their most recent acquisition was Kairos Therapeutics on Mar 22, 2016. They acquired Kairos Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Mar 22, 2016
Kairos Therapeutics
|
Biotechnology | acquisition | — | Detail |
